Abstract: A circuit with a Safe-Torque-Off (STO) functionality and a frequency converter including the same are provided. According to embodiments, the circuit may include a first STO channel configured to control on/off of power supply to a high-side driver of a frequency converter based on a first STO signal, a second STO channel configured to control on/off of power supply to a low-side driver of the frequency converter based on a second STO signal, and a third STO channel configured to control supply of a drive control signal from a controller of the frequency converter to the high-side driver and the low-side driver based on a result of a logical operation of the first STO signal and the second STO signal, wherein the logical operation is configured to make the result active in response to at least one of the first and second STO signals being active.

Abstract: The disclosure relates to a bioactive molecule conjugate, preparation methods and use thereof, particularly relates to a novel bioactive molecule conjugate obtained by improving coupling of the drug and the targeting moiety in an ADC or SMDC, as well as its preparation method and use in the manufacture of a medicament for the treatment of a disease associated with an abnormal cell activity.

Abstract: Related is an anti-CLDN 18.2 antibody-drug conjugate, preparation method and use thereof. The antibody-drug conjugate and the composition thereof is capable of effectively binding CLDN 18.2 and inhibiting the growth of Claudin 18.2 positive tumors. Further related is a pharmaceutical composition comprising the antibody-drug conjugate or the composition, and use of the pharmaceutical composition in the preparation of a medicament for preventing and/or treating tumors.

Abstract: A semiconductor device is provided. The semiconductor device includes a base layer having a first side for forming memory cells and a second side that is opposite to the first side. The semiconductor device includes a stack of alternating word line layers and insulating layers that is positioned over the first side of the base layer, where the stack includes a first region and a second region. A channel structure extends through the first region of the stack in a vertical direction and further extends into the base layer from the first side. A plurality of connection structures are formed over the second side of the base layer and include a first connection structure that is coupled to the channel structure.

Abstract: The present invention provides an anti-ErbB2 antibody-drug conjugate, a composition comprising the conjugate, a method for preparing the conjugate, and use of the conjugate.

Abstract: Provided is an anti-PD-L1 antibody preparation, including an anti-PD-L1 antibody, a buffer solution and sodium chloride, without added sugars and/or sugar alcohols. Also provided is the use of the anti-PD-L1 antibody preparation in the preparation of drugs for preventing and/or treating and/or adjuvant treating and/or diagnosing a tumor or anemia.

Abstract: A semiconductor device is provided. The semiconductor device includes a base layer having a first side for forming memory cells and a second side that is opposite to the first side. The semiconductor device includes a stack of alternating word line layers and insulating layers that is positioned over the first side of the base layer, where the stack includes a first region and a second region. A channel structure extends through the first region of the stack in a vertical direction and further extends into the base layer from the first side. A plurality of connection structures are formed over the second side of the base layer and include a first connection structure that is coupled to the channel structure.

Abstract: A fabricating method of a semiconductor device is provided. A temporary semiconductor structure is provided. The temporary semiconductor structure includes a temporary substrate and a conductive layer, the temporary substrate has a first surface, the conductive layer is disposed on the first surface of the temporary substrate, and the conductive layer includes one or more first trace. Then, a recess is formed in the temporary semiconductor structure to form a first semiconductor structure and a first substrate. The recess penetrates through the first substrate and expose the one or more first trace. Thereafter, an input/output pad is formed in the recess and on the one or more first trace.

Abstract: Provided are a chimeric antigen receptor (CAR) or CAR construct containing antibodies against BCMA and CD19, a nucleic acid molecule encoding the CAR or CAR construct, a modified immune cell, and a method for preparing the immune cell. The CAR or CAR construct and the modified immune cell are used for the prevention and/or treatment of B cell related conditions (e.g., B cell and plasma cell related malignant tumors or autoimmune diseases (such as systemic lupus erythematosus)), and can effectively avoid target escape and prevent the recurrence of multiple myeloma.

Abstract: This application provides a display control method, an electronic device, and a computer-readable storage medium. The method includes: displaying a multi-task interface if a first touch operation event entered by a user on a touchscreen of the electronic device is detected, where the first touch operation event is used to start the multi-task interface; and displaying a one-hand operation interface on the electronic device if a second touch operation event entered by the user on the touchscreen is detected in the multi-task interface.

Abstract: The present application relates to the field of treatment of diseases, and in particular, to an anti-CLDN18.2 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding said antibody and fragment, and method for preparing said antibody and fragment. The anti-CLDN18.2 antibody or the antigen-binding fragment thereof has high specificity and affinity to CLDN18.2, and can effectively bind to CLDN18.2 and mediate the killing of CLDN18.2 expressing cells. Therefore, the present application further relates to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and use thereof in the preparation of drugs, wherein the drugs are used for the prevention and/or treatment of tumors.

Abstract: The present invention relates to the field of treatment of diseases and immunology. Specifically, the present invention relates to an anti-LAG-3 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding said antibody and fragment, and method for preparing said antibody and fragment. The anti-LAG-3 antibody or the antigen-binding fragment thereof according to the present invention has high specificity and high affinity to LAG-3, can effectively block the binding of LAG-3 to MHC II and/or FGL1, and can inhibit and/or block intracellular signaling mediated by LAG-3 binding to MHC II and/or FGL1. Therefore, the present invention further relates to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and use of the pharmaceutical composition in the preparation of drugs.

Abstract: In certain aspects, a semiconductor device includes a first semiconductor layer, a first semiconductor structure formed on the first semiconductor layer including a main chip region, and seal ring discontinuous contact structures formed in a seal ring region enclosing the main chip region. Each seal ring discontinuous contact structure includes a seal ring body portion and a through silicon contact (TSC) portion penetrating through the first semiconductor layer and coupled to the seal ring body portion.

Abstract: The present disclosure provides an exciter and an electronic product. The exciter comprises: a magnetic circuit assembly comprising a first housing and a magnet, and the magnet is connected to the first housing; a coil assembly comprising a second housing and a coil, and the coil is disposed in a magnetic field formed by the magnet, wherein the coil assembly is configured to be capable of generating a vibration relative to the magnetic circuit assembly, the coil is formed by winding a wire having a polygonal cross section. According to the present disclosure, the coil wire has a polygonal cross section, so that an interval between the wires can be reduced in the wound coil, the number of turns of the coil is increased in the same space, the effective length of the coil is increased, and the driving force generated from the coil is increased.

Abstract: Embodiments of this application relate to the field of terminal technologies, and describe a method for displaying a dynamic image and a terminal, which resolve a problem that power consumption of a terminal caused by an existing method in which three-dimensional real-time rendering is used is relatively high. The method may be applied to a terminal, and can includes obtaining, from a video file based on a preset factor, a plurality of pieces of image frame data in a one-to-one correspondence to a plurality of image frames. The method may also include decoding the plurality of pieces of image frame data, to obtain the plurality of image frames. Furthermore, the method can include successively displaying the plurality of image frames obtained through the decoding, to present the dynamic image.

Abstract: Related are an anti-TSLP antibody or an antigen-binding fragment thereof, nucleic acid molecules coding the same, and a method for preparing the same. The anti-TSLP antibody or the antigen-binding fragment thereof have high affinity to TSLP, capable of effectively binding with TSLP and blocking the proliferative effect of TSLP with respect to Ba/F3-hTSLPR-hIL7R? cells, and blocking the capability of TSLP in activating and secreting cytokines with respect to PBMC. At the same time, further related are a medicinal composition comprising the antibody or the antigen-binding fragment thereof, and uses of the composition in preparing a medicament for preventing and/or treating asthma, allergic inflammation, an allergic reaction or autoimmune disease.

Abstract: Embodiments of this application relate to the field of terminal technologies, and describe a method for displaying a dynamic image and a terminal, which resolve a problem that power consumption of a terminal caused by an existing method in which three-dimensional real-time rendering is used is relatively high. The method may be applied to a terminal, and can includes obtaining, from a video file based on a preset factor, a plurality of pieces of image frame data in a one-to-one correspondence to a plurality of image frames. The method may also include decoding the plurality of pieces of image frame data, to obtain the plurality of image frames. Furthermore, the method can include successively displaying the plurality of image frames obtained through the decoding, to present the dynamic image. The dynamic image includes the plurality of image frames, and the preset factor includes at least one of the following factors: a time point and orientation data.

Abstract: A semiconductor device and a fabricating method thereof are provided. The semiconductor device includes a semiconductor structure and an input/output pad. The semiconductor structure includes a first substrate and a conductive layer, in which the first substrate has a first surface and a second surface opposite to each other, the conductive layer is disposed on the first surface of the first substrate, and the conductive layer includes one or more first trace. The first semiconductor structure has a recess penetrating the first substrate and exposing the one or more first trace, and the input/output pad is disposed on the one or more first trace and in the recess.

Abstract: Aspects of the disclosure provide a semiconductor device. The semiconductor device includes a first die and a second die boned face-to-face. The first die includes first transistors formed on a face side of the first die in a semiconductor portion and at least a contact structure disposed in an insulating portion outside the semiconductor portion. The second die includes a substrate and second transistors formed on a face side of the second die. Further, the semiconductor device includes a first pad structure disposed on a back side of the first die and the first pad structure is conductively coupled with the contact structure. An end of the contact structure protrudes from the insulating portion into the first pad structure. Further, in some embodiments, the semiconductor device includes a connection structure disposed on the back side of the first die and conductively connected with the semiconductor portion.

Abstract: Provided are a recombinant bispecific antibody against CTLA-4 and PDL-1, a nucleic acid molecule for encoding the antibody, a vector and a host cell comprising the nucleic acid molecule, and a method for preparing the antibody. Also provided are a pharmaceutical composition comprising the bispecific antibody, and usage of the bispecific antibody in preparation of the pharmaceutical composition.